Coya Therapeutics, Inc. (NASDAQ:COYA) CFO David S. Snyder Purchases 1,800 Shares of Stock

Coya Therapeutics, Inc. (NASDAQ:COYA) CFO David S. Snyder purchased 1,800 shares of the firm’s stock in a transaction on Thursday, November 14th. The stock was acquired at an average price of $7.19 per share, with a total value of $12,942.00. Following the completion of the transaction, the chief financial officer now owns 8,800 shares in the company, valued at approximately $63,272. This trade represents a 25.71 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Coya Therapeutics Stock Performance

Shares of COYA stock traded down $0.16 during mid-day trading on Friday, hitting $6.65. The company’s stock had a trading volume of 8,696 shares, compared to its average volume of 71,443. The company’s fifty day simple moving average is $7.11 and its 200-day simple moving average is $7.01. Coya Therapeutics, Inc. has a 52 week low of $4.75 and a 52 week high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.15. As a group, equities research analysts expect that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current year.

Hedge Funds Weigh In On Coya Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after buying an additional 750,338 shares in the last quarter. GHP Investment Advisors Inc. acquired a new stake in Coya Therapeutics in the third quarter valued at approximately $169,000. Renaissance Technologies LLC bought a new stake in shares of Coya Therapeutics during the second quarter valued at approximately $101,000. Finally, Gilbert & Cook Inc. bought a new position in shares of Coya Therapeutics in the 2nd quarter worth $61,000. Institutional investors own 39.75% of the company’s stock.

Analysts Set New Price Targets

COYA has been the topic of several analyst reports. Chardan Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Monday.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.